Abstract: Congestive heart failure with reduced ejection fraction is still a chronic and progressive syndrome that brings huge burden for the whole economic and health systems. Despite remarkable advances in guideline-directed medical therapy and device-based treatment over the last few years, patients in such scenarios have a high residual risk of cardiovascular adverse events, especially during worsening heart failure. As a novel soluble guanylate cyclase stimulator, Vericiguat may play a role in management of congestive heart failure. Herein, we summarized the research progress of Vericiguat in management of congestive heart failure with reduced ejection fraction.